Peripheral Nervous System Neoplasms - 25 Studies Found
Active, not recruiting |
: Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis :
|
Active, not recruiting |
: Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1) : Neurofibromatoses : 2012-09-05 :
|
Completed |
: Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas : Neurofibromatosis : 2012-08-22 : Drug: Gleevec Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects |
Withdrawn |
: Proton Radiation Therapy for Spinal Tumors :
: 2012-03-13 :
|
Suspended |
: Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas :
: 2011-07-25 : Drug: Sutent®/Sunitinib Upon enrollment, subjects will receive Sutent® orally. Adults (Age > |
Completed |
: Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas :
: 2011-01-11 : Drug: Tasigna Following enrollment each subject will initially receive Tasigna orally at 200 mg twice da |
Active, not recruiting |
: Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas :
: 2010-06-08 : Drug: Gleevec Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with |
Active, not recruiting |
: First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas : Cutaneous Neurofibromas : 2009-06-15 : Procedure: Erbium-YAG laser vaporization spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequen |
Active, not recruiting |
: Medical Treatment of "High-Risk" Neurofibromas : Neurofibromatosis 1 : 2009-01-16 :
|
Terminated |
: Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas : Neurofibroma : 2008-07-14 : Drug: LS11 LS11 will be given as a one-time IV infusion over 3-5 minutes. |